AT III was less substituted in anti-Xa group O'Meara et al. anti-Xa 0.4-0.8 0.45 ± 0.15 0.44 ± 0.08 Strong: r = 0.68 (p < 0.01) No: Anti-Xa-based UFH management protocol is feasible, decreases blood sampling and heparin infusion adjustments, and does not increase complications ...
The flow-chart describing participant inclusion is shown in Fig. 1. Description of the study population A total of 131 patients (55 in the RCA group and 76 in the systemic heparin group) were included in the analysis. The demographic and clinical characteristics of the patients were largely ...
Patients assigned to receive subcutaneous low-molecular-weight heparin also received an intravenous placebo bolus and a continuous intravenous infusion of placebo throughout initial therapy. To maintain double-blinding, APTTs were reported only to a member of the health care team not involved in ...